Search Results
Your search for it matches 15455 pages
Showing 5201 - 5250Do Men Treated With ADT for Prostate Cancer Have a Lower Risk of Acquiring COVID-19?
A study of 4,532 men in the Veneto region of Italy has found that those who were being treated for prostate cancer with androgen-deprivation therapies (ADT) were less likely to develop COVID-19, and if they were infected, their disease tended to be less severe. This research was published by...
FDA Pipeline: Two Breakthrough Therapy Designations for Fam-Trastuzumab Deruxtecan-nxki, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designations for an antibody-drug conjugate in the treatment of gastric and lung cancers. The Agency has also issued Orphan Drug designations for agents being investigated in chronic myeloid...
10 Changes I Will Make in My Oncology Practice as a Result of COVID-19
As a result of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or COVID-19) global pandemic, medicine—including oncology practice—will never be the same. We find ourselves in a time of emergency medicine for all specialties, technologic innovation (eg, more prevalent use of...
Study Finds a High Rate of Intra- and Postoperative Conversions to Total Thyroidectomy
The overall risk of needing a total thyroidectomy was found to be 19.4% for patients undergoing lobectomy for indeterminate and high-risk thyroid nodule, according to a report published by Moore et al in the World Journal of Surgery. The study also found that 21% and 26.5% of patients originally...
Jennifer K. Litton, MD, on Breast Cancer: EMBRACA Trial on Talazoparib vs Chemotherapy
Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, discusses study results of talazoparib vs chemotherapy in patients with BRCA1/2-mutated HER2-negative advanced breast cancer. In this final analysis, patient-reported outcomes continued to favor the PARP inhibitor, even...
Videoconference Intervention Can Reduce Levels of Anxiety and Distress Among Distance Caregivers
According to the National Alliance for Caregiving, the number of adult individuals in the United States providing care for patients with cancer ranges between 2.8 million and 6.1 million. Caregivers for patients with cancer who live more than 1 hour away report having higher levels of anxiety and...
Expert Point of View: William Dale, MD, PhD
"We have known for a long time, based on good evidence, that geriatric assessment is good at accurately identifying patients at high risk for chemotherapy-induced toxicity, surgical complications, and increased hospitalizations. This study adds an intervention component based on the geriatric...
Geriatrician Assessment and Integrated Care May Help Older Patients as Well as the Health-Care System
A full geriatric assessment and geriatrician-led multidisciplinary care improved the quality of life of patients aged 70 and older undergoing chemotherapy, targeted therapy, or immunotherapy, according to results of a prospective, randomized, controlled, open-label trial, reported in a press...
Cancer vs COVID-19: Clinical Trial Research During the Pandemic
The COVID-19 pandemic transformed cancer care, seemingly overnight, as practices scrambled to ensure a safe environment for caregivers and patients. Although regulatory burdens have been relaxed to allow patients to continue on trial treatment and telemedicine has expanded its competency and reach, ...
How the Lung Cancer Community Came Together During the COVID-19 Pandemic
The COVID-19 pandemic (caused by infection with the SARS-CoV-2 coronavirus) has created a host of diagnostic, treatment, and follow-up problems for patients with cancer of all types, and this is particularly true for patients with lung cancer, their families, and providers. Everyone wanted to...
AACR 2020: Continuous Dosing of Dabrafenib Plus Trametinib Improves Progression-Free Survival vs Intermittent Dosing in Advanced Melanoma
Continuous dosing with dabrafenib and trametinib improved progression-free survival in patients with BRAF-mutated advanced melanoma compared with an intermittent-dosing strategy, according to results of the phase II SWOG S1320 randomized trial reported at the opening Plenary Session of the 2020...
Don’t Touch Me With a 6-Foot Pole
The universe has an intriguing way of registering our wishes and delivering them in convoluted, mutated forms. Last winter, I recall coming home after a long day at the hospital and being ambushed by my 3-year-old daughter and preteen son. She wanted to play, he needed help with homework, and they ...
Can a Culturally Tailored Education Program Improve Colorectal Cancer Awareness and Screening?
People who received information from the Screen to Save program, a culturally tailored initiative from the National Cancer Institute (NCI) Center to Reduce Cancer Health Disparities (CRCHD), increased their knowledge of colorectal cancer and indicated willingness to adopt potentially preventive...
Half of Surveyed Cancer Researchers Report Their Work Is on Hold Due to the COVID-19 Pandemic
A survey of American Cancer Society grantees found that about half reported their cancer research has been halted as a result of the COVID-19 pandemic. The American Cancer Society reached out to all of its funded researchers to assess the state of their projects and collect information to guide...
Financial Support Available to Providers During COVID-19 Pandemic
The Coronavirus Aid, Relief, and Economic Security (CARES) Act and new guidance from the Centers for Medicare & Medicaid Services (CMS) both contain provisions to provide financial support to qualified providers. ASCO strongly encourages providers to immediately begin meticulously documenting...
My ASCO Journey: Opportunities for Gratitude and Breaking Glass Ceilings
In my native language, there is a saying that is translated as, “A child who does not travel only appreciates their mother’s cooking.” In the broad sense, as we grow up and experience the different things that life has to offer, two things happen if we allow our minds to open up: we realize there...
Ongoing Efforts Toward Vaccine Development for COVID-19
Coronavirus disease 2019 (COVID-19) is spreading throughout the world, and vaccine developers have responded with unprecedented speed. Since the COVID-19 genome sequence was released in January, human trials of an experimental vaccine candidate have already begun in the Seattle area. Although the...
I Have Multiple Myeloma and Am Concerned About the Coronavirus
In hindsight, the symptoms I began experiencing in the fall of 2013—sudden excruciating back bone pain and severe fatigue—should have tipped me off that I had a serious disease, but 7 years ago, they were easy to explain away. The bone pain was similar to what I had experienced several years...
Yoga for Pediatric and Adolescent Patients With Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Despite significant improvements reported in survival rates, symptom management in pediatric...
Global COVID-19 Observatory and Resource Center for Childhood Cancer
St. Jude Children’s Research Hospital, in partnership with the International Society of Paediatric Oncology (SIOP), has launched the Global COVID-19 Observatory and Resource Center for Childhood Cancer. The website offers health-care providers around the world a space to share the latest...
Larry Kwak, MD, PhD, Named AIMBE Fellow
City of Hope recently announced that Larry Kwak, MD, PhD, has been inducted into the 2020 Class of American Institute for Medical and Biological Engineering (AIMBE) Fellows. Dr. Kwak is Vice President and Deputy Director of City of Hope’s Comprehensive Cancer Center. He has pioneered breakthrough...
Durvalumab Plus Chemotherapy for Extensive-Stage Small Cell Lung Cancer
On March 27, 2020, durvalumab (Imfinzi) was approved for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer.1,2 Supporting Efficacy Data Approval was based on the findings of the open-label phase III ...
Grace and Forgiveness
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Encorafenib Combined With Cetuximab in Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer
On April 8, 2020, encorafenib was approved for use in combination with cetuximab for the treatment of previously treated adult patients with metastatic colorectal cancer with a BRAF V600E mutation detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 Encorafenib is not indicated...
Understanding Patient-Reported Outcomes in Cancer Trials: A Beginner’s Guide
Patient-reported outcomes are measures used in clinical trials to capture aspects of a patient’s health condition, reported directly by the patient, without introduction of bias from third parties. They are distinct from the physical toxicities reported by clinicians1 and are collected using a...
The Role of Adipose Tissue in Cancer Aggressiveness
Over the past decade, obesity has been linked to an increased risk and aggressiveness of numerous cancer types. Many biologic activities within adipose tissue change with obesity and may contribute to carcinogenesis and the initiation of cancer. To shed light on the current state of knowledge in...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, Myeloma, and Myelodysplastic Syndromes
The 2019 American Society of Hematology (ASH) Annual Meeting & Exposition featured a cornucopia of sessions. It was impossible to attend all the lectures, symposia, oral presentations, poster presentations, and special events because many were concurrent. Below, we have selected some...
American Cancer Society Awards New Research, Training Grants
The American Cancer Society (ACS) has approved funding for 79 research and training grants, totaling $36,165,100 in the first of two grant cycles for 2020. Grant applications were reviewed and approved remotely in light of the coronavirus epidemic. The grants will fund investigators at 59...
Pooled Analysis Supports Benefit of Dual HER2-Targeted Therapy, but Questions Remain
In the treatment of HER2-positive early breast cancer, patients who receive dual HER2-targeted therapy in both the neoadjuvant and adjuvant settings are less likely to experience recurrence than those who received dual therapy only as neoadjuvant treatment, according to a pooled analysis of...
KEYNOTE-522: A Biomarker Resource for PD-1 Inhibition in Early Triple-Negative Breast Cancer
In the phase III KEYNOTE-522 trial reported in The New England Journal of Medicine and reviewed in this issue of The ASCO Post, Schmid et al1 found that the addition of pembrolizumab to neoadjuvant chemotherapy in stage II or III triple-negative breast cancer significantly improved the pathologic...
Expert Point of View: Virginia Kaklamani, MD, DSc, and Minetta Liu, MD
Virginia Kaklamani, MD, DSc, Professor of Medicine and Head of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, moderated a press conference where Milan Radovich, PhD, reported the robust ability of circulating tumor DNA (ctDNA) and circulating tumor cells to predict...
Studies Show Circulating Tumor Material May Predict Outcomes After Neoadjuvant Therapy for Breast Cancer
In early triple-negative breast cancer, the presence of circulating tumor DNA (ctDNA) and circulating tumor cells after neoadjuvant chemotherapy may enable risk stratification of patients for disease recurrence and may predict outcomes, according to a preplanned correlative analysis of the phase II ...
Expert Point of View: Basem M. William, MD, MRCP (UK), FACP, and Caron Jacobson, MD
Basem M. William, MD, MRCP (UK), FACP, Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center, Columbus, said many of the new-generation bispecific antibodies are “highly promising.” He said they “are...
Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers
Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...
Joint Guideline Sheds Light on Management of Hereditary Breast Cancer
As germline genetic testing becomes more widespread among patients with breast cancer, recommendations for the appropriate management of patients with hereditary breast cancer are needed. Until now, no ASCO guideline has addressed the management of hereditary breast cancer, even for carriers of...
Vascular Imaging for Detection of Breast Cancer: Best of Two Worlds?
For breast imaging, contrast-enhanced mammography, which uses the anatomic imaging of a mammogram in addition to imaging neovascularity, can offer the overall screening capability of standard mammography and the sensitivity of magnetic resonance imaging (MRI) at a fraction of the cost of MRI,...
Timothy Chan, MD, PhD, Named Director of Cleveland Clinic’s Center for Immunotherapy and Precision Immuno-Oncology
Timothy Chan, MD, PhD, has been appointed Director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic. Dr. Chan will lead the new center to bring together multidisciplinary experts from across the Cleveland Clinic enterprise to advance research and treatment related...
Can Breast Cancer Surgery Be Eliminated in ‘Exceptional Responders’ to Neoadjuvant Therapy?
Can patients with breast cancer who achieve an “exceptional response” to neoadjuvant therapy safely forgo surgery? That is a question being seriously explored in multinational trials. “We’ve known for a long time that we can eliminate disease in many patients if they have chemosensitive tumors....
Early Signs of Activity With Immunotherapies in Low-Incidence Cancers
Immunotherapy is showing promise for patients with rare cancers, offering new treatment opportunities and clinical trials to those with previously limited options. At the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium, presenters discussed the use of immunotherapy in three low-incidence cancers: ...
Expert Point of View: Omid Hamid, MD
Omid Hamid, MD, Chief of Research/Immuno-Oncology, The Angeles Clinic & Research Institute, and Co-Director of the Cutaneous Malignancy Program at Cedars-Sinai Cancer Center, Los Angeles, commented on these two studies for The ASCO Post. According to Dr. Hamid, the findings for the tumor...
New Guideline on Systemic Therapy for Melanoma Tackles Rapid Developments in Treatment Options
Systemic treatment of melanoma has changed rapidly since the introduction of ipilimumab in 2011. Newer therapies approved for melanoma since that time include immunotherapy, targeted therapy for mutation-bearing tumors, and injectional therapy for cutaneous or palpable lesions. ASCO has released...
PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer
Based on multiple phase III prospective trials, there is evidence that both PARP inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG 218, ICON7, SOLO-1, PRIMA,...
Prioritizing Patients With Metastatic Disease for Palliative Radiotherapy
In anticipation of how the COVID-19 pandemic might impact oncology care as the coronavirus spread across New York City, radiation oncologists with expertise in the management of metastatic disease and inpatient oncologic emergencies at Memorial Sloan Kettering Cancer Center (MSK) met in late winter ...
Distinct New MDS Subtype Proposed Based on Presence of Genetic Mutation
In a special report published by Malcovati et al in the journal Blood, an international working group of experts in myelodysplastic syndromes (MDS) has proposed the recognition of a distinct subtype of MDS based on the presence of a nonheritable genetic mutation that causes the disease. The...
Expert Point of View: Alexandra Leary, MD, PhD
Alexandra Leary, MD, PhD, of the Gustave Roussy Institute of Oncology, Paris, underscored the controversy surrounding the use of neoadjuvant chemotherapy in advanced ovarian cancer, suggesting the discord may be “more cultural and emotional than scientific” to some degree. “Some countries, such as ...
SGO 2020: Wee1 Inhibition in Recurrent Uterine Serous Carcinoma
In a clinical trial in patients with recurrent uterine serous carcinoma, one-third of study participants responded to treatment with the Wee1 inhibitor adavosertib, according to data presented by Liu et al at a virtual session of the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s...
Mehdi Hamadani, MD: In My Experience Question 6
Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic? Recorded April 21, 2020.
Mortality Rate of Patients With Cancer and COVID-19 in a New York Hospital
Patients with cancer who were infected with COVID-19 were much more likely to die from the disease than those without cancer, according to research from physician-researchers at Montefiore Health System and Albert Einstein College of Medicine. Their findings were published by Mehta et al in Cancer...
Expert Point of View: Charles Sawyers, MD
“The hypothesis of combining kinase inhibitors with checkpoint inhibitors could be a fantastic idea,” said formal study discussant Charles Sawyers, MD, of Memorial Sloan Kettering Cancer Center, New York. “This trial [IMspire150] is positive, and that is great news. Triple therapy is superior to...
Treating Colorectal Cancer in the Time of COVID-19
The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing the risk of COVID-19...
